Short- and Long-Term Outcomes of Radiofrequency Ablation for Early Hepatocellular Carcinoma with Liver Dysfunction
Authors:
- Sijie XiaoSXSijie Xiao
- Yuzheng YanYYYuzheng Yan
- Huaqiang BiHBHuaqiang Bi
- Tengqian TangTTTengqian Tang
- Kai FengKFKai Feng
- Feng XiaFXFeng Xia
- Chunlin TangCTChunlin Tang
- Kuansheng MaKMKuansheng Ma
- Qiang WangQWQiang Wang
Open Access
- 1 March 2026
- journal article
- Published by Taylor & Francis in Journal of Hepatocellular Carcinoma
- Vol. ume 13, 1-13
Abstract
This study aimed to report the short- and long-term outcomes of radiofrequency ablation (RFA) for the treatment of patients with early hepatocellular carcinoma (HCC) with different levels of liver dysfunction. This retrospective study included early HCC patients with Child-Pugh score (CPS) ≥ 7 cirrhosis who underwent percutaneous RFA at our center. The short-term efficacy of RFA was evaluated based on postoperative technical success, effectiveness, and complications, and long-term efficacy was evaluated based on recurrence-free survival (RFS) and overall survival (OS). The impact of liver dysfunction on both outcomes was explored. In total, 176 patients (median age, 57 years; 149 males) were included. The technical success rate, technical effectiveness, and incidence of postoperative major complications were 96.6%, 97.7%, and 3.4%, respectively. There were no significant differences between the groups divided according to CPS. The 1-, 3-, and 5-year RFS rates were 54.1%, 28.8%, and 16.8%, respectively, no significant differences were observed between the groups divided by Child-Pugh score (p = 0.057), Albumin-Bilirubin grade (p = 0.170), or Model for End-stage Liver Disease score (p=0.210). The 1-, 3-, and 5-year OS rates were 91.3%, 67.1%, and 58.5%, respectively, and OS decreased as ALBI grade increased (p = 0.015). Multivariate Cox analysis demonstrated that male patient (hazard ratio, 2.31; p = 0.013) and recurrent HCC (hazard ratio, 2.347; p < 0.001) were independent predictive factors for RFS; hypertension (hazard ratio, 2.828; p = 0.042) and tumor number (hazard ratio, 2.445; p = 0.011) were independent predictive factors for OS, respectively. Radiofrequency ablation is safe and effective for early HCC patients with early hepatocellular carcinoma and liver dysfunction.Keywords
This publication has 30 references indexed in Scilit:
- The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022ESMO Open, 2023
- Liver Function Assessment Using Albumin–Bilirubin Grade for Patients with Very Early-Stage Hepatocellular Carcinoma Treated with Radiofrequency AblationDigestive Diseases and Sciences, 2017
- Comparison of no-touch multi-bipolar vs. monopolar radiofrequency ablation for small HCCJournal of Hepatology, 2017
- Ablation of hepatocellular carcinomaBest Practice & Research Clinical Gastroenterology, 2014
- Clinical effectiveness of bipolar radiofrequency ablation for small liver cancersJournal of Gastroenterology, 2012
- A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinomaJournal of Hepatology, 2012
- Mortality and morbidity of hepatectomy, radiofrequency ablation, and embolization for hepatocellular carcinoma: a national survey of 54,145 patientsJournal of Gastroenterology, 2012
- Mortality and complication rates of percutaneous ablative techniques for the treatment of liver tumors: a systematic reviewEuropean Radiology, 2011
- Percutaneous radiofrequency ablation for hepatocellular carcinomaCancer, 2005
- Transection of the oesophagus for bleeding oesophageal varicesBritish Journal of Surgery, 1973